UK Markets closed
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • FTSE 250

    22,336.10
    +266.79 (+1.21%)
     
  • AIM

    1,236.38
    +11.54 (+0.94%)
     
  • GBP/EUR

    1.1602
    -0.0025 (-0.21%)
     
  • GBP/USD

    1.4102
    +0.0050 (+0.3582%)
     
  • BTC-GBP

    34,527.29
    -565.19 (-1.61%)
     
  • CMC Crypto 200

    1,398.33
    +39.77 (+2.93%)
     
  • S&P 500

    4,173.85
    +61.35 (+1.49%)
     
  • DOW

    34,382.13
    +360.68 (+1.06%)
     
  • CRUDE OIL

    65.51
    +1.69 (+2.65%)
     
  • GOLD FUTURES

    1,844.00
    +20.00 (+1.10%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     
  • HANG SENG

    28,027.57
    +308.90 (+1.11%)
     
  • DAX

    15,416.64
    +216.96 (+1.43%)
     
  • CAC 40

    6,385.14
    +96.81 (+1.54%)
     

Global Tumor / Cancer Markers Market to Reach $3.7 Billion by 2027

ReportLinker
·13-min read

Abstract: - Global Tumor / Cancer Markers Market to Reach $3. 7 Billion by 2027. - Amid the COVID-19 crisis, the global market for Tumor / Cancer Markers estimated at US$2.

New York, April 21, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Tumor / Cancer Markers Industry" - https://www.reportlinker.com/p06033174/?utm_source=GNW
1 Billion in the year 2020, is projected to reach a revised size of US$3.7 Billion by 2027, growing at a CAGR of 8.1% over the period 2020-2027.
- The U.S. Market is Estimated at $575.1 Million, While China is Forecast to Grow at 12.2% CAGR
- The Tumor / Cancer Markers market in the U.S. is estimated at US$575.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$835.2 Million by the year 2027 trailing a CAGR of 12.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.

- Select Competitors (Total 35 Featured) -

  • Abbott Diagnostics Ltd.

  • Affymetrix, Inc.

  • Agilent Technologies, Inc.

  • Beckman, Dickinson and Company (BD) Diagnostics

  • BioCurex

  • BioModa, Inc.

  • Clarient, Inc.

  • Correlogic Systems, Inc.

  • Epigenomics AG

  • Gen-Probe, Inc.




Read the full report: https://www.reportlinker.com/p06033174/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Tumor / Cancer
Markers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Tumor / Cancer Markers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Tumor / Cancer Markers
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 4: USA Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 5: USA Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

CANADA
Table 6: Canada Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 7: Canada Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

JAPAN
Table 8: Japan Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 9: Japan Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

CHINA
Table 10: China Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 11: China Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

EUROPE
Table 12: Europe Current & Future Analysis for Tumor / Cancer
Markers by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 13: Europe Historic Review for Tumor / Cancer Markers by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 14: Europe 15-Year Perspective for Tumor / Cancer Markers
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

FRANCE
Table 15: France Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 16: France Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

GERMANY
Table 17: Germany Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 18: Germany Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

ITALY
Table 19: Italy Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 20: Italy Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

UNITED KINGDOM
Table 21: UK Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 22: UK Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

SPAIN
Table 23: Spain Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 24: Spain Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

RUSSIA
Table 25: Russia Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 26: Russia Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

REST OF EUROPE
Table 27: Rest of Europe Current & Future Analysis for Tumor /
Cancer Markers by Segment - Tumor / Cancer Markers -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 28: Rest of Europe Historic Review for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

ASIA-PACIFIC
Table 29: Asia-Pacific Current & Future Analysis for Tumor /
Cancer Markers by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 30: Asia-Pacific Historic Review for Tumor / Cancer
Markers by Geographic Region - Australia, India, South Korea
and Rest of Asia-Pacific Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 31: Asia-Pacific 15-Year Perspective for Tumor / Cancer
Markers by Geographic Region - Percentage Breakdown of Value
Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2020 & 2027

AUSTRALIA
Table 32: Australia Current & Future Analysis for Tumor /
Cancer Markers by Segment - Tumor / Cancer Markers -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 33: Australia Historic Review for Tumor / Cancer Markers
by Segment - Tumor / Cancer Markers Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

INDIA
Table 34: India Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 35: India Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

SOUTH KOREA
Table 36: South Korea Current & Future Analysis for Tumor /
Cancer Markers by Segment - Tumor / Cancer Markers -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 37: South Korea Historic Review for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

REST OF ASIA-PACIFIC
Table 38: Rest of Asia-Pacific Current & Future Analysis for
Tumor / Cancer Markers by Segment - Tumor / Cancer Markers -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 39: Rest of Asia-Pacific Historic Review for Tumor /
Cancer Markers by Segment - Tumor / Cancer Markers Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

LATIN AMERICA
Table 40: Latin America Current & Future Analysis for Tumor /
Cancer Markers by Geographic Region - Argentina, Brazil, Mexico
and Rest of Latin America Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2020 through 2027 and %
CAGR

Table 41: Latin America Historic Review for Tumor / Cancer
Markers by Geographic Region - Argentina, Brazil, Mexico and
Rest of Latin America Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: Latin America 15-Year Perspective for Tumor / Cancer
Markers by Geographic Region - Percentage Breakdown of Value
Sales for Argentina, Brazil, Mexico and Rest of Latin America
Markets for Years 2012, 2020 & 2027

ARGENTINA
Table 43: Argentina Current & Future Analysis for Tumor /
Cancer Markers by Segment - Tumor / Cancer Markers -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 44: Argentina Historic Review for Tumor / Cancer Markers
by Segment - Tumor / Cancer Markers Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

BRAZIL
Table 45: Brazil Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 46: Brazil Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

MEXICO
Table 47: Mexico Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 48: Mexico Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

REST OF LATIN AMERICA
Table 49: Rest of Latin America Current & Future Analysis for
Tumor / Cancer Markers by Segment - Tumor / Cancer Markers -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 50: Rest of Latin America Historic Review for Tumor /
Cancer Markers by Segment - Tumor / Cancer Markers Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

MIDDLE EAST
Table 51: Middle East Current & Future Analysis for Tumor /
Cancer Markers by Geographic Region - Iran, Israel, Saudi
Arabia, UAE and Rest of Middle East Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 52: Middle East Historic Review for Tumor / Cancer
Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE
and Rest of Middle East Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 53: Middle East 15-Year Perspective for Tumor / Cancer
Markers by Geographic Region - Percentage Breakdown of Value
Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle
East Markets for Years 2012, 2020 & 2027

IRAN
Table 54: Iran Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 55: Iran Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

ISRAEL
Table 56: Israel Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 57: Israel Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

SAUDI ARABIA
Table 58: Saudi Arabia Current & Future Analysis for Tumor /
Cancer Markers by Segment - Tumor / Cancer Markers -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 59: Saudi Arabia Historic Review for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

UNITED ARAB EMIRATES
Table 60: UAE Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 61: UAE Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

REST OF MIDDLE EAST
Table 62: Rest of Middle East Current & Future Analysis for
Tumor / Cancer Markers by Segment - Tumor / Cancer Markers -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 63: Rest of Middle East Historic Review for Tumor /
Cancer Markers by Segment - Tumor / Cancer Markers Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

AFRICA
Table 64: Africa Current & Future Analysis for Tumor / Cancer
Markers by Segment - Tumor / Cancer Markers - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 65: Africa Historic Review for Tumor / Cancer Markers by
Segment - Tumor / Cancer Markers Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

IV. COMPETITION
Total Companies Profiled: 35
Read the full report: https://www.reportlinker.com/p06033174/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001